Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

Background: The detection of pro-oncogenic mutations such as mutations in the epidermal
growth factor receptor (EGFR) allowed the development of targeted therapies as inhibitor of …

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase
inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR …

Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …

Purpose This study aims to understand the effects and long-term survival of 1st generation
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Lung cancer with EGFR mutation is often associated pathological characteristics and good
responses to EGFR tyrosine kinase inhibitors (TKIs). However, certain types of rare EGFR …

Nowadays, EGFR-TKIs (epidermal growth factor receptor-tyrosine kinase inhibitors) targeted
therapy is well established treatment for patients with the so-called EGFR common …

Background The significance of uncommon EGFR mutations in newly diagnosed advanced
non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …